Cytosorbents ( (CTSO) ) has issued an update.
On February 25, 2025, CytoSorbents Corporation announced the expiration of its Series A Right Warrants, resulting in $1.6 million in gross proceeds from their exercise. This event, combined with previous fundraising efforts, has strengthened the company’s balance sheet by increasing net liquidity to approximately $12.3 million. The proceeds are intended to support innovation and expansion in CytoSorbents’ core international business and aid in the potential U.S. and Canadian approval of their DrugSorb™-ATR product in 2025. The company also highlighted the ongoing progress of their regulatory applications with the U.S. FDA and Health Canada, expecting decisions in 2025.
More about Cytosorbents
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. Their proprietary technologies utilize biocompatible, highly porous polymer beads to remove toxic substances from blood, with applications in removing blood thinners during surgery and inflammatory agents in critical illnesses. CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries, with ongoing development of the DrugSorb™-ATR system for U.S. and Canadian markets.
YTD Price Performance: 18.48%
Average Trading Volume: 278,010
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $59.76M
Find detailed analytics on CTSO stock on TipRanks’ Stock Analysis page.